Saturday, December 12, 2009

MK-0752 kills lingering breast CSC

Experimental Drug Kills Breast Cancer Stem Cells In Early Trials by Julie Steenhuysen, Reuters, December 11, 2009 [Another link][FriendFeed entry]. First two paragraphs:
An experimental drug was effective at killing breast cancer stem cells -- a kind of master cancer cell that resists chemotherapy, U.S. researchers said on Friday.
Studies in animals and women with advanced breast cancer showed the experimental compound MK-0752, under development by Merck & Co Inc (MRK.N), was able to kill off cancer stem cells that linger in the breast after chemotherapy.
The NCI Drug Dictionary entry for MK-0752:
A synthetic small molecule with potential antineoplastic activity. MK0752 inhibits the Notch signaling pathway, which may result in induction of growth arrest and apoptosis in tumor cells in which the Notch signaling pathway is overactivated. The Notch signaling pathway plays an important role in cell-fate determination, cell survival, and cell proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Posted by at
Labels: , , , ,

1 comment:

  1. Jim TillDecember 12, 2009 at 1:32 PM

    See also: Experimental drug targets chemo-resistant breast cancer stem cells, News Release, Baylor College of Medicine, December 11, 2009 [Another link].

    And: Targeting Intrinsically-Resistant Breast Cancer Stem Cells with Gamma-Secretase Inhibitors by Jenny C Chang and 12 co-authors, including Max S Wicha, Abstract #48, General Session IV, 32nd San Antonio Breast Cancer Symposium, December 11, 2009.

    And: Drugs in the Pipeline: What’s Emerging in Late-stage Trials, AACR News, December 11, 2009.

    ReplyDelete

Subscribe to: Post Comments (Atom)